A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Seeks partnership between government and private medical colleges for providing superior medical education
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
To create leading company developing medicines targeting metalloenzymes
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The company is one of the most profitable companies manufacturing speciality chemicals in India
Krishna Institute of Medical Sciences to consider raising Rs. 300 crores
Cipla and Ethris partner for the development of mRNA-based therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
